Not yet recruiting
D2 Gastrectomy With or Without Para-Aortic Lymph Node Dissection After Chemoimmunotherapy for Gastric Cancer
NCT07912606· Phase 2· The First Affiliated Hospital with Nanjing Medical University· Source
Contact: Hao Xu, MD, PhD
Not yet recruiting
Lymph Node Dissection After Neoadjuvant Therapy for Gastric and EGJ Adenocarcinoma
NCT07902596· The First Affiliated Hospital with Nanjing Medical University· Source
Contact: Hao Xu, MD, PhD
Not yet recruiting
A Prospective, Single-Arm, Multicenter, Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) Combined With Cetuximab and mFOLFIRI Regimen as First-Line Treatment for Recurrent or Metastatic Colorectal Cancer
NCT07874438· The First Affiliated Hospital with Nanjing Medical University· Source
Contact: Zan Fu
Recruiting
Perioperative Retlirafusp Alfa(Anti-PD-L1/TGF-β Bifunctional Fusion Protein) Plus Famitinib and GEMOX-Based Hepatic Arterial Infusion Chemotherapy for Locally Advanced Intrahepatic Cholangiocarcinoma: A Multicenter, Single-Arm, Exploratory Phase II Trial
NCT07847710· Phase 2· The First Affiliated Hospital with Nanjing Medical University· Source
Contact: Jianhua Rao Professor Rao, Ph.D.
Not yet recruiting
Safety and Efficacy of Esketamine - Dexmedetomidine Combination Versus Dexmedetomidine Monotherapy for Hyperactive Delirium in ICU Patients on Non-Invasive Respiratory Support (SEED-NIRS Trial): Study Protocol of a Randomized Controlled Trial
NCT07377981· Phase 4· The First Affiliated Hospital with Nanjing Medical University· Source
Contact: Xiangrong Zuo
Recruiting
Heart Rate Variability Changes and Postoperative Delirium After Major Abdominal Surgery
NCT07783464· The First Affiliated Hospital with Nanjing Medical University· Source
Contact: Junbei Wu
Recruiting
Intra-arterial Thrombolysis For Acute Ischemic Stroke With Medium Vessel Occlusion
NCT07668323· Phase 3· The First Affiliated Hospital with Nanjing Medical University· Source
Contact: Xinglong Liu, Doctor
Not yet recruiting
Safety and Efficacy of RN9101 in the Treatment of Relapsed/Refractory Multiple Myeloma
NCT07628595· Early phase 1· The First Affiliated Hospital with Nanjing Medical University· Source
Contact: Lei Fan
Recruiting
MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)
NCT07479485· Phase 1/2· Lepu Biopharma Co., Ltd.· Source
Contact: Xiangcheng Li
Recruiting
Disitamab Vedotin Combined With SOX Regimen Versus SOX Alone as Adjuvant Therapy for HER2-Moderate/High Expressing Stage Ⅲ Gastric Cancer: A Prospective, Multicenter, Randomized, Phase Ⅱ Clinical Trial
NCT07474324· Phase 2· The First Affiliated Hospital with Nanjing Medical University· Source
Contact: Hao Xu
Recruiting
7-Day Vonoprazan, High-Dose Amoxicillin, and Bismuth Therapy
NCT07232095· Phase 4· The First Affiliated Hospital with Nanjing Medical University· Source
Contact: Feng Ye, PhD
Recruiting
β-alanine in the Treatment of Advanced Hepatocellular Carcinoma
NCT07317414· Phase 2· Peking Union Medical College Hospital· Source
Contact: Lin Lu
Recruiting
A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple Myeloma
NCT07294625· Early phase 1· The First Affiliated Hospital with Nanjing Medical University· Source
Contact: Xuxing Shen
Recruiting
A Phase II, Multicenter, Randomized, Controlled Clinical Study Comparing the Efficacy and Safety of Sintilimab Plus SOX Versus SOX Alone as Adjuvant Therapy for PD-L1-Positive, Stage pN3 Gastric Cancer
NCT07263386· Phase 2· The First Affiliated Hospital with Nanjing Medical University· Source
Contact: Xu Hao, M.D Ph.D
Recruiting
Study in Human iPSCs-derived RPE Cells Transplantation for Advanced (Late-stage) AMD
NCT07418177· Phase 1/2· The First Affiliated Hospital with Nanjing Medical University· Source
Contact: Yue Wang
Not yet recruiting
Anti-IL-5 Therapy With Simple Polypectomy Versus Extended Endoscopic Sinus Surgery for CRSwNP
NCT07200336· Phase 4· Eye & ENT Hospital of Fudan University· Source
Contact: Meiping Lu, PhD
Recruiting
An Exploratory Clinical Study on the Safety and Efficacy of Autologous NK Cells in the Treatment of Pulmonary Nodules
NCT07185035· Early phase 1· The First Affiliated Hospital with Nanjing Medical University· Source
Contact: yongqian Shu, Dr
Not yet recruiting
Brentuximab Vedotin Combined With R-CHP in Newly Diagnosed EBV+ DLBCL-NOS
NCT06925555· Phase 2· The First Affiliated Hospital with Nanjing Medical University· Source
Contact: WEI XU
Not yet recruiting
A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma
NCT07131501· Phase 2· The First Affiliated Hospital with Nanjing Medical University· Source
Contact: Xuehao Wang
Not yet recruiting
RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies
NCT07113496· Phase 1· The First Affiliated Hospital with Nanjing Medical University· Source
Contact: Lei Fan
Not yet recruiting
Maintenance Chemotherapy With S-1 vs. Observation After Adjuvant Therapy for Resected Pancreatic Cancer With High Risk of Recurrence/Metastasis
NCT06779318· Phase 4· The First Affiliated Hospital with Nanjing Medical University· Source
Contact: Min Tu, Master
Recruiting
ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
NCT07327034· Phase 2· Abbisko Therapeutics Co, Ltd· Source
Contact: Xiangcheng Li
Recruiting
An Exploratory Clinical Study of CD19 CAR NK Cells for the Treatment of Refractory Antisynthetase Antibody Syndrome and Rheumatoid Arthritis
NCT06613490· Early phase 1· The First Affiliated Hospital with Nanjing Medical University· Source
Contact: Wenfeng Tan, PhD, MD
Recruiting
VA Dual Sequential Therapy
NCT06929962· Phase 4· The First Affiliated Hospital with Nanjing Medical University· Source
Contact: Feng Ye, PhD
Recruiting
Real-World Study of PADN for the Treatment of PAH
NCT07039604· Pulnovo Medical (Wuxi) Co., Ltd.· Source
Contact: Shao-liang Chen, MD
Recruiting
Impact of Pre-Ablation Prehabilitation on Clinical Outcomes and Cardiorespiratory Fitness in Atrial Fibrillation Patients
NCT07270757· Nanjing Medical University· Source
Contact: Kexin Wang
Recruiting
Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer.
NCT07394387· Phase 2· The First Affiliated Hospital with Nanjing Medical University· Source
Contact: Wenbin Zhou, PhD
Recruiting
Neuroprotective Effects of Long-term TaVNS in Early Parkinson's Disease Patients
NCT06665113· Kezhong Zhang· Source
Contact: Kezhong Zhang
Active, not recruiting
Adebrelimab Combined With Irinotecan Liposomal (II), Oxaliplatin, and 5-FU/LV Conversion Therapy for Locally Advanced Pancreatic Cancer
NCT06766019· Phase 2· The First Affiliated Hospital with Nanjing Medical University· Source
Recruiting
Interventional Treatment of Chronic Tinnitus With Acoustic Stimulation
NCT07185061· The First Affiliated Hospital with Nanjing Medical University· Source
Contact: The First Affiliated Hospital with Nanjing Medical University
Active, not recruiting
MRI and CT in Gastroesophageal Junction or Upper Gastric Adenocarcinoma
NCT06640153· The First Affiliated Hospital with Nanjing Medical University· Source
Recruiting
Chidamide Plus R-CHOP in Newly Diagnosed Double-Expressor Diffuse Large B-Cell Lymphoma With Other Molecular Subtypes
NCT06891157· Phase 2· The First Affiliated Hospital with Nanjing Medical University· Source
Contact: Wei Xu
Not yet recruiting
Henagliflozin's Impact on Prediabetes Remission
NCT06448130· Phase 4· Shandong Provincial Hospital· Source
Contact: Xiude Fan, MD&PhD
Recruiting
Aspirin vs. Rivaroxaban for Thromboprophylaxis in Multiple Myeloma
NCT07907211· Phase 4· Chen Lijuan· Source
Contact: Lijuan Chen
Recruiting
Clinical Study Protocol of IAV-induced Remission Followed by Consolidation Therapy With MDCyta+Ven in ND-AML
NCT06232694· The First Affiliated Hospital with Nanjing Medical University· Source
Contact: Ming Hong, MD
Recruiting
Disitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd Failure: A Phase II Study
NCT07446452· Phase 2· The First Affiliated Hospital with Nanjing Medical University· Source
Contact: Li Wei, Ph.D
Recruiting
RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II Study
NCT07065435· Phase 2· The First Affiliated Hospital with Nanjing Medical University· Source
Contact: Wei Li, Ph.D
Recruiting
CSP Versus BiVP for Heart Failure Patients With RVP Upgraded to Cardiac Resynchronization Therapy
NCT06241651· The First Affiliated Hospital with Nanjing Medical University· Source
Contact: Jiangang Zou
Recruiting
The Efficacy and Safety of the COMBO Endoscopy Oropharyngeal Airway in Gastrointestinal Endoscopy Procedure
NCT06081647· RenJi Hospital· Source
Contact: Cunming Liu, Dr.
Recruiting
OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM
NCT06182696· Phase 1/2· OriCell Therapeutics Co., Ltd.· Source
Contact: Jianyong Li
Recruiting
A Randomized Controlled Trial of LOT-CRT Versus conventionaL BiVP in Heart Failure Patients With NICD
NCT06061627· The First Affiliated Hospital with Nanjing Medical University· Source
Contact: Jiangang Zou
Recruiting
Effect of PCI on Clinical Prognosis of Chronic Coronary Artery Occlusion
NCT06542653· The First Affiliated Hospital with Nanjing Medical University· Source
Contact: Lei Jiang
Active, not recruiting
Lobectomy-First vs. Lymphadenectomy-First for Operable NSCLC (LOFTY)
NCT06577792· Sun Yat-sen University· Source
Recruiting
A Clinical Study of Inhaled Nitric Oxide in Moderate-to-Severe Chronic Obstructive Pulmonary Disease
NCT05896800· The First Affiliated Hospital with Nanjing Medical University· Source
Contact: Linfu Zhou, Doctor
Recruiting
A Clinical Study of Inhaled Nitric Oxide in Patients With Chronic Obstructive Pulmonary Disease
NCT07382258· Novlead Inc.· Source
Contact: Ning Ding, Doctor
Recruiting
Clinical Study Protocol of Maintenance Therapy With Venetoclax in Elderly Patients With AML in First Complete Remission
NCT05909293· The First Affiliated Hospital with Nanjing Medical University· Source
Contact: Ming Hong
Active, not recruiting
LBBP as Initial Therapy in Patients With Non-ischemic Heart Failure and LBBB
NCT05572957· The First Affiliated Hospital with Nanjing Medical University· Source
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer
NCT05346224· Phase 3· Shanghai Henlius Biotech· Source
Recruiting
Unrelated Umbilical Cord Blood Stem Cell Combined With Azacitidine Based Treatment for Advanced MDS,CMML-2 and sAML
NCT05584761· Phase 1/2· The First Affiliated Hospital with Nanjing Medical University· Source
Contact: Fei Huang, MD
Recruiting
Corheart 6: Long-term Cohort Study
NCT07094919· China National Center for Cardiovascular Diseases· Source
Contact: Yongfeng Shao
Showing 50 of 51.